FSD1抗体—艾普蒂

+ +

•  

   

     Western blot analysis of APOC3 expression in human plasma lysate.    

  
  

The FSD1 antibody targets the Fibronectin type III and SPRY domain-containing protein 1 (FSD1), a protein encoded by the FSD1 gene in humans. FSD1 is characterized by two conserved structural domains: a fibronectin type III (FN3) domain, known for its role in cell adhesion and extracellular matrix interactions, and a SPRY domain, which often mediates protein-protein interactions. While the full functional scope of FSD1 remains under investigation, studies suggest its involvement in cellular processes such as cytoskeletal organization, signal transduction, and tissue development. It is expressed in various tissues, including the brain, kidney, and reproductive organs, with altered expression levels observed in certain cancers, neurological disorders, and fibrotic diseases.

FSD1 antibodies are primarily utilized as research tools to investigate the protein's expression patterns, subcellular localization, and interactions in both physiological and pathological contexts. In cancer research, FSD1 has been explored as a potential biomarker due to its dysregulation in tumors, though its role (oncogenic or tumor-suppressive) appears context-dependent. Additionally, FSD1's association with neural development and synaptic function has prompted studies in neurodegenerative conditions. The antibody's applications extend to immunohistochemistry, Western blotting, and immunofluorescence, aiding in mechanistic studies and therapeutic target validation. Recent interest also focuses on FSD1's interaction with signaling pathways like Wnt and TGF-β, highlighting its potential as a modulator of disease progression. Ongoing research aims to clarify its precise biological functions and therapeutic relevance.